292 related articles for article (PubMed ID: 29750868)
21. Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of
Biegała Ł; Kołat D; Gajek A; Płuciennik E; Marczak A; Śliwińska A; Mikula M; Rogalska A
Cells; 2024 May; 13(10):. PubMed ID: 38786089
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Li L; Karanika S; Yang G; Wang J; Park S; Broom BM; Manyam GC; Wu W; Luo Y; Basourakos S; Song JH; Gallick GE; Karantanos T; Korentzelos D; Azad AK; Kim J; Corn PG; Aparicio AM; Logothetis CJ; Troncoso P; Heffernan T; Toniatti C; Lee HS; Lee JS; Zuo X; Chang W; Yin J; Thompson TC
Sci Signal; 2017 May; 10(480):. PubMed ID: 28536297
[TBL] [Abstract][Full Text] [Related]
23. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.
Evers B; Schut E; van der Burg E; Braumuller TM; Egan DA; Holstege H; Edser P; Adams DJ; Wade-Martins R; Bouwman P; Jonkers J
Clin Cancer Res; 2010 Jan; 16(1):99-108. PubMed ID: 20008842
[TBL] [Abstract][Full Text] [Related]
24. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
Konecny GE; Kristeleit RS
Br J Cancer; 2016 Nov; 115(10):1157-1173. PubMed ID: 27736844
[TBL] [Abstract][Full Text] [Related]
25. Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.
Frankum J; Moudry P; Brough R; Hodny Z; Ashworth A; Bartek J; Lord CJ
Oncotarget; 2015 May; 6(13):10746-58. PubMed ID: 25883215
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.
Mukhopadhyay A; Drew Y; Matheson E; Salehan M; Gentles L; Pachter JA; Curtin NJ
Biochem Pharmacol; 2019 Sep; 167():125-132. PubMed ID: 30342021
[TBL] [Abstract][Full Text] [Related]
27. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
Bianchi A; Lopez S; Altwerger G; Bellone S; Bonazzoli E; Zammataro L; Manzano A; Manara P; Perrone E; Zeybek B; Han C; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Newberg JY; Pavlick DC; Elvin J; Frampton GM; Schwartz PE; Santin AD
Gynecol Oncol; 2019 Oct; 155(1):144-150. PubMed ID: 31434613
[TBL] [Abstract][Full Text] [Related]
28. Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.
Mani C; Tripathi K; Chaudhary S; Somasagara RR; Rocconi RP; Crasto C; Reedy M; Athar M; Palle K
Neoplasia; 2021 Sep; 23(9):1002-1015. PubMed ID: 34380074
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma.
Xu Y; Spear S; Ma Y; Lorentzen MP; Gruet M; McKinney F; Xu Y; Wickremesinghe C; Shepherd MR; McNeish I; Keun HC; Nijhuis A
Cell Rep; 2023 Oct; 42(10):113307. PubMed ID: 37858464
[TBL] [Abstract][Full Text] [Related]
30. Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
Liu X; Jiang Y; Nowak B; Qiang B; Cheng N; Chen Y; Plunkett W
Cancer Chemother Pharmacol; 2018 Feb; 81(2):255-267. PubMed ID: 29189915
[TBL] [Abstract][Full Text] [Related]
31. Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer.
Lee JM; Gordon N; Trepel JB; Lee MJ; Yu M; Kohn EC
J Transl Med; 2015 Jul; 13():239. PubMed ID: 26198537
[TBL] [Abstract][Full Text] [Related]
32. Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair.
Ida N; Okura M; Tanaka S; Hosono N; Yamauchi T
Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38785163
[TBL] [Abstract][Full Text] [Related]
33. DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors.
Wang T; Kyle AH; Baker JHE; Liu NA; Banáth JP; Teymori S; Minchinton AI
DNA Repair (Amst); 2024 Jul; 139():103689. PubMed ID: 38749239
[TBL] [Abstract][Full Text] [Related]
34. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
Ding L; Kim HJ; Wang Q; Kearns M; Jiang T; Ohlson CE; Li BB; Xie S; Liu JF; Stover EH; Howitt BE; Bronson RT; Lazo S; Roberts TM; Freeman GJ; Konstantinopoulos PA; Matulonis UA; Zhao JJ
Cell Rep; 2018 Dec; 25(11):2972-2980.e5. PubMed ID: 30540933
[TBL] [Abstract][Full Text] [Related]
35. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
Orhan E; Velazquez C; Tabet I; Fenou L; Rodier G; Orsetti B; Jacot W; Sardet C; Theillet C
Cancer Lett; 2024 May; 589():216820. PubMed ID: 38574883
[TBL] [Abstract][Full Text] [Related]
36. An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer.
Gonzalez-Ochoa E; Oza AM
Clin Cancer Res; 2023 Jul; 29(14):2563-2566. PubMed ID: 37191665
[TBL] [Abstract][Full Text] [Related]
37. Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity.
Motonari T; Yoshino Y; Haruta M; Endo S; Sasaki S; Miyashita M; Tada H; Watanabe G; Kaneko T; Ishida T; Chiba N
Sci Rep; 2024 Apr; 14(1):7519. PubMed ID: 38589490
[TBL] [Abstract][Full Text] [Related]
38. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
Lee JM; Ledermann JA; Kohn EC
Ann Oncol; 2014 Jan; 25(1):32-40. PubMed ID: 24225019
[TBL] [Abstract][Full Text] [Related]
39. CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
Xie XF; Wu NQ; Wu JF; Zhang GL; Guo JF; Chen XL; Du CW
Cancer Lett; 2022 Dec; 551():215944. PubMed ID: 36209974
[TBL] [Abstract][Full Text] [Related]
40. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
Mao Y; Huang X; Shuang Z; Lin G; Wang J; Duan F; Chen J; Li S
Cancer Med; 2018 Apr; 7(4):1285-1296. PubMed ID: 29479816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
